Relationship between low T3 syndrome and NT-proBNP levels in non-cardiac patients

References

• Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501–9.
   Google Scholar
• Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syn-drome”. Endocr Rev 1982; 3: 164–216.
   Google Scholar
• De Groot U. Dangerous dogmas in medicine: the nonthy-roidal illness syndrome. J Clin Endocr Metab 1999; 84: 151–64.
   Google Scholar
• Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scar-lattini M, L’Abbate A, Donato L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003; 107: 708–13.
   Google Scholar
• Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005; 118: 132–6.
   Google Scholar
• Shanoudy H, Soliman A, Moe S, Hadian D, Veldhuis JD, Iranmanesh A, Russel DC. Early manifestation of ‘sick euthyroid’ syndrome in patients with compensated chronic heart failure. J Card Fail 2001; 7: 146–52.
   Google Scholar
• Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42: 728–35.
   Google Scholar
• Tsutamoto T, Wada A, Moeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshima M. Attenua-tion of compensation of endogenous cardiac natriuretic pep-tide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circula-tion 1997; 96: 509–16.
   Google Scholar
• Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P. Rouleau JL, Tendera M, Castaigne D, Anker SD, Amann-Zalan I, Hoersch S, Katus HA. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780–6.
   Google Scholar
• Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. Titration of vasodilatator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemo-dynamic and neumendocrine effects of tailored versus empir-ical therapy. Am Heart J 1999; 138: 1126–32.
   Google Scholar
• Richards AM, Troughton R, Lainchbury J, Doughty R, Wright S. Guiding and monitoring of heart failure therapy with NT-proBNP: concepts and clinical studies. J Card Fail 2005; 11 (5 suppl): S34-7.
   Google Scholar
• Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dys-function. A community-based study. Circulation 2004; 109: 3176–81.
   Google Scholar
• Mark DB, Felker GM. B-type natriuretic peptide - A bio-marker for all seasons? N Engl J Med 2004; 350: 718-20.
   Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classifica-tion, and stratification. Am J Kidney Dis 2002; 39: S1–S266.
   Google Scholar
• Feldman T, Borow KM, Same DH, Neumann A, Lang RM. Myocardial mechanics in hyperthyroidism: importance of left ventricular loading conditions, heart rate and contrac-tile state. J Am Coll Cardiol 1986; 7: 967–74.
   Google Scholar
• Klein, Ojamaa K. The cardiovascular system in hypothy-roidism. In: Braverman LE, Utiger RD, editors. Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Test. 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2000: 777-82.
   Google Scholar
• Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NE De Marchi D, Lombardi M, L’Abbate A, Iervasi G. Does subclinical hypothyroidism affect cardiac pump per-formance? J Am Coll Cardiol 2005; 45: 439–45.
   Google Scholar
• Friberg L, Werner S, Eggertsen G, Ahnve S. Rapid down-reg-ulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med 2002; 162: 1388–94.
   Google Scholar
• Holland FW, Brown PS Jr, Weintraub BD, Clark RE. Car-diopulmonary bypass and thyroid function: a “euthyroid sick sindrome”. Ann Thorac Surg 1991; 52: 46–50.
   Google Scholar
• Camacho PM, Dwarkanathan AA. Sick euthyroid syndrome. What to do when thyroid function tests are abnormal in crit-ically ill patients. Postgrad Med 1999; 105: 215–9.
   Google Scholar
• Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 1990; 16: 91–5.
   Google Scholar
• Ascheim DD, Hryniewicz K. Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothy-ronine state. Thyroid 2002; 12: 511–5.
   Google Scholar
• Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745–51.
   Google Scholar
• Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Inves-tigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005; 149: 744–50.
   Google Scholar
• Willis MS, Lee ES, Grenache DG. Effect of anemia on plasma concentrations of NT-proBNP. Clin Chim Acta 2005; 358: 175–81.
   Google Scholar
• Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kemp-son ME, Lamb EJ. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kid-ney Dis 2005; 46: 610–20.
   Google Scholar
• Raizada V, Thakore K, Luo W, McGuire PG. Cardiac cham-ber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 2001; 16: 137–40.
   Google Scholar
• Clark BA, Elahi D, Shannon RP, Wei JY, Epstein FH. Influ-ence of age and dose on the end-organ responses to atrial natri-uretic peptide in humans. Am J Hypertens 1991; 4: 500–7.
   Google Scholar
• Muscari A, Berzigotti A, Bianchi G, Giannoni C, Ligabue A, Magalotti D, Sbano D, Zacchini A, Zoli M. Non-car-diac determinants of NT-proBNP levels in the elderly: Rel-evance of haematocrit and hepatic steatosis. Eur J Heart Fail 2006; 5: 468–76.
   Google Scholar
• Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655–63.
   Google Scholar
• Magnusson M, Melander 0, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of NT-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004; 27: 1929–35.
   Google Scholar
• Lubien E, De Maria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Garretto N, Wanner E, Maisel AS. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595–601.
   Google Scholar
• Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, Hon M, Lim YJ, Mishima M, Masuyama T. Ele-vation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertro-phy. J Am Coll Cardiol 2004; 43: 55–60.
   Google Scholar
• Katzeff HL, Powell SR, Ojamaa K. Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am J Physiol 1997; 273: E951–E956.
   Google Scholar
• Forini F, Paolicchi A, Pizzorusso T, Ratto GM, Saviozzi M, Vanini V, Iervasi G. 3,5,31-triiodothyronine deprivation affects phenotype and intracellular (Ca2+)I of human car-diomyocytes in culture. Cardiovasc Res 2001; 51: 322–30.
   Google Scholar
• Slag MF, Morley JE, Elson MK, Crowson TW, Nuttal FQ, Shafer RB. Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 1981; 245: 43–5.
   Google Scholar
• Sumita S, Ujike Y, Namiki A, Watanabe H, Kawamata M, Watanabe A, Satoh 0. Suppression of the thyrotropin response to thyrotropin-releasing hormone and its associa-tion with severity of critical illness. Crit Care Med 1994; 22: 1603–9.
   Google Scholar
• Schultz M, Faber J, Kistorp C, Jarlov A, Pedersen F, Wiin-berg N, Hildebrandt P. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf) 2004; 60: 54–9.
   Google Scholar
• Hamilton MA, Stevenson LW, Fonarow GC. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 1998; 81: 443–7.
   Google Scholar
• Mullis-Jansson SL, Argenziano M, Corwin S, Homma S, Weinberg AD, Williams M, Rose EA, Smith CR. A ran-domized double-blind study of the effect of triiodothyro-nine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 1999; 117: 1128–34.
   Google Scholar